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Introduction
Fibroblast growth fact 23 (FGF23) is a phosphate- and 1,25(OH)2 vita-
min D–regulating (1,25D-regulating) hormone produced by osteo-
blasts and osteocytes (1). FGF23 acts via FGF receptor 1 (FGFR1) 
coupled with the coreceptor αKlotho to reduce expression of sodium 
phosphate cotransporters (NaPi-2a and -2c) and renal 25-hydroxy 
vitamin D 1-α-hydroxylase (2). FGF23 lowers serum phosphorus and 
1,25D levels by its actions on the kidney to reduce renal tubular reab-
sorption of phosphate (TRP) and 1,25D production. Excess FGF23 
has been implicated in a number of hypophosphatemic disorders, 
such as tumor-induced osteomalacia (3), X-linked hypophosphate-
mia (4), and autosomal dominant hypophosphatemic rickets (5).
Hyperphosphatemic familial tumoral calcinosis (HFTC)/
hyperostosis-hyperphosphatemia syndrome (HHS) (OMIM 
211900) is a disorder of FGF23 deficiency or resistance. Affected 
individuals develop ectopic calcifications called tumoral calcino-
sis and/or diaphyseal hyperostosis, which manifests clinically in 
the long bones as diaphyseal pain and swelling (6). Characteristic 
dental findings of HFTC/HHS include shortened roots with dilac-
erations, thistle-shaped dental pulps, pulp chamber and root canal 
obliteration, and pulp stones (7). In addition, some patients expe-
rience systemic inflammation.
HFTC/HHS is an autosomal recessive disease, and to date, 
causal mutations in 3 genes have been identified: FGF23 (12p13.3) 
(8), UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 
3 (GALNT3) (2q24-q31) (9), and Klotho (KL) (13q12) (10). Muta-
tions in FGF23 and GALNT3 result in premature cleavage of bio-
logically active intact FGF23 (iFGF23) into inactive fragments, 
while mutations in KL interrupt FGF23 signaling, causing FGF23 
resistance. Lack of iFGF23 results in hyperphosphatemia, due 
to increased TRP and elevated or inappropriately normal 1,25D 
production, which promotes gastrointestinal absorption of phos-
phorus and calcium. The net effect is an increase in the calcium × 
phosphate product, leading to tumoral calcinosis.
Here, we present what we believe is the first case of autoim-
mune hyperphosphatemic tumoral calcinosis due to pathogenic 
FGF23 autoantibodies. Autoantibodies directed against extra-
cellular targets, such as receptors (e.g., nicotinic acetylcholine 
receptor autoantibodies in myasthenia gravis) or secreted mole-
Hyperphosphatemic familial tumoral calcinosis (HFTC)/hyperostosis-hyperphosphatemia syndrome (HHS) is an autosomal 
recessive disorder of ectopic calcification due to deficiency of or resistance to intact fibroblast growth factor 23 (iFGF23). 
Inactivating mutations in FGF23, N-acetylgalactosaminyltransferase 3 (GALNT3), or KLOTHO (KL) have been reported as 
causing HFTC/HHS. We present what we believe is the first identified case of autoimmune hyperphosphatemic tumoral 
calcinosis in an 8-year-old boy. In addition to the classical clinical and biochemical features of hyperphosphatemic tumoral 
calcinosis, the patient exhibited markedly elevated intact and C-terminal FGF23 levels, suggestive of FGF23 resistance. 
However, no mutations in FGF23, KL, or FGF receptor 1 (FGFR1) were identified. He subsequently developed type 1 diabetes 
mellitus, which raised the possibility of an autoimmune cause for hyperphosphatemic tumoral calcinosis. Luciferase 
immunoprecipitation systems revealed markedly elevated FGF23 autoantibodies without detectable FGFR1 or Klotho 
autoantibodies. Using an in vitro FGF23 functional assay, we found that the FGF23 autoantibodies in the patient’s plasma 
blocked downstream signaling via the MAPK/ERK signaling pathway in a dose-dependent manner. Thus, this report describes 
the first case, to our knowledge, of autoimmune hyperphosphatemic tumoral calcinosis with pathogenic autoantibodies 
targeting FGF23. Identification of this pathophysiology extends the etiologic spectrum of hyperphosphatemic tumoral 
calcinosis and suggests that immunomodulatory therapy may be an effective treatment.
Autoimmune hyperphosphatemic tumoral calcinosis  
in a patient with FGF23 autoantibodies
Mary Scott Roberts,1 Peter D. Burbelo,2 Daniela Egli-Spichtig,3 Farzana Perwad,3 Christopher J. Romero,4 Shoji Ichikawa,5  
Emily Farrow,6 Michael J. Econs,5,7 Lori C. Guthrie,1 Michael T. Collins,1 and Rachel I. Gafni1
1Skeletal Disorders and Mineral Homeostasis Section, and 2Dental Clinical Research Core, National Institute of Dental and Craniofacial Research (NIDCR), NIH, Bethesda, Maryland, USA. 3Department of 
Pediatrics, Division of Nephrology, UCSF School of Medicine, San Francisco, California, USA. 4Department of Pediatric Endocrinology and Diabetes, Icahn School of Medicine at Mount Sinai, New York, 
New York, USA. 5Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. 6Center for Pediatric Genomic Medicine, Children’s Mercy Hospital, Kansas City, Missouri, USA. 
7Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Conflict of interest: The NIDCR has received financial support from Shire, Novartis, 
and BridgeBio for research using pharmaceutical agents not discussed in this work. MSR 
became an employee of Ultragenyx Pharmaceutical in September 2017, after work on 
this project was completed. Indiana University has licensed FGF23 to Kyowa Hakko Kirin 
Co., and MJE receives royalty income through this license. MJE serves as a consultant to 
Ultragenyx Pharmaceutical and receives research support from Horizon Pharma for an 
unrelated trial.
License: Copyright 2018, American Society for Clinical Investigation.
Submitted: May 7, 2018; Accepted: September 11, 2018.
Reference information: J Clin Invest. 2018;128(12):5368–5373. 
https://doi.org/10.1172/JCI122004.
The Journal of Clinical Investigation   C O N C I S E  C O M M U N I C A T I O N
5 3 6 9jci.org   Volume 128   Number 12   December 2018
At 7 years, 3 months, the 
patient was referred to the NIH, 
and acetazolamide was added to 
promote renal phosphate excre-
tion. After 9 months on this 
regimen, the right hip tumoral 
calcinosis was decreased in size 
on physical exam and repeat 
radiograph (Figure 1, A–D) and 
no new lesions had developed. 
The blood phosphorus fluctuat-
ed, but decreased overall, with a 
nadir of 5.4 mg/dl (Supplemen-
tal Figure 1; supplemental mate-
rial available online with this 
article; https://doi.org/10.1172/
JCI122004DS1).
Given the considerably ele-
vated iFGF23 and CFGF23 lev-
els in this patient compared with 
reported cases of HFTC/HHS 
and lack of an identifiable genet-
ic cause, we questioned whether 
an interfering antibody led to 
falsely elevated iFGF23 and 
CFGF23 levels. Therefore, we 
performed serial dilutions of the patient’s plasma (1:1, 1:10, 1:20, 
1:50, 1:100, 1:500, 1:1000) and measured iFGF23 and CFGF23 via 
second-generation ELISA kits (Immutopics). For both iFGF23 and 
CFGF23, levels decreased with serial dilution as expected, except 
for the 1:500 and 1:1000 dilutions of iFGF23, which were below 
the lower limit of detection of the assay (Supplemental Table 1). 
The ability to detect dilutions of iFGF23 and CFGF23 via ELISA 
ruled out the presence of an interfering antibody resulting in the 
elevated iFGF23 and CFGF23 levels.
Twenty months after initial symptom onset, the patient report-
ed a 2-week history of polyuria, polydipsia, and nocturia, with 
no change in appetite or weight. He denied dysuria, hematuria, 
enuresis, or fever. Laboratory evaluation revealed blood phospho-
rus of 5.6 mg/dl (normal for age, 3–5.7), 1,25D of 59 pg/ml (nor-
mal, 24–86), and TRP of 93% (normal, 85%–95% in the setting of 
normal blood phosphorus). iFGF23 and CFGF23 levels remained 
markedly elevated at 6900 pg/ml (normal, <52) and 22,400 RU/
ml (normal for age ≤230), respectively. In addition, the subject was 
hyperglycemic (fasting blood glucose, 433 mg/dl; normal, < 120) 
and insulinopenic (4.1 mcU/ml; normal fasting, 2.6–24.9) with a 
low C-peptide (0.8 ng/ml; normal, 1.1–1.5). Hemoglobin A1c was 
elevated at 10.7% (estimated average glucose, 260 mg/dl) (Table 
1). The subject had positive islet antigen-2 (IA-2) and antiinsulin 
antibodies and negative glutamic acid decarboxylase (GAD65) 
antibodies. Of note, he had a normal fasting blood glucose of 81 
mg/dl 3 months prior. These results were consistent with new- 
onset T1DM. The patient was admitted for initiation of insulin 
therapy and diabetes education.
Given the lack of an identifiable genetic cause for hyperphos-
phatemic tumoral calcinosis and the new diagnosis of T1DM, we 
hypothesized that the tumoral calcinosis could be autoimmune 
cules (e.g., granulocyte-macrophage–stimulating factor autoanti-
bodies in pulmonary alveolar proteinosis), have been previously 
described as causing human disease (11). In this case, the patient 
exhibited classic features of HFTC/HHS: tumoral calcinosis with 
hyperphosphatemia in the setting of normal renal function and 
increased TRP. iFGF23 levels were high, suggesting FGF23 resis-
tance. However, a causative genetic mutation was not identified. 
After the patient subsequently developed type 1 diabetes mellitus 
(T1DM), an autoimmune disease, luciferase immunoprecipitation 
systems (LIPS) (12) were used to detect potential autoantibodies 
against proteins in the FGF23-signaling receptor complex. An in 
vitro FGF23 functional assay was performed to assess the effect of 
FGF23 autoantibodies on FGF23 signal transduction.
Results and Discussion
This White boy presented at 6 years, 3 months, with pain, swell-
ing, and development of a firm lesion on the lateral right hip. MRI 
of the lesion revealed a calcified mass in the right gluteus maxi-
mus extending into the subcutaneous soft tissue. A biopsy of the 
lesion showed tumoral calcinosis. Subsequent laboratory eval-
uation revealed hyperphosphatemia (7.2 mg/dl; normal for age, 
3.2–6.3) with normal blood calcium and renal function, consistent 
with the diagnosis of HFTC/HHS. iFGF23 and C-terminal FGF23 
(CFGF23) levels were markedly elevated, at 13,000 pg/ml (nor-
mal, <52) and 33,000 RU/ml (normal for age, ≤230) (Table 1), 
respectively, consistent with FGF23 resistance. The patient was 
started on the phosphate binder sevelamer and a low-phosphate 
diet. Sequencing of FGF23, KL, and FGFR1 genes and whole- 
exome sequencing did not identify gene mutations or genetic vari-
ants, including mutations and/or variants in GALNT3, that could 
explain the clinical calcinosis/phosphate phenotype.
Table 1. Biochemical results in patient with autoimmune tumoral calcinosis
6 yr, 7 mo (initial 
 laboratory evaluation) 
7 yr, 3 mo 7 yr, 9 mo 8 yr
Treatment SEV SEV, ACZ SEV, ACZ
Phosphorus (3.2–6.3 mg/dl) 7.2 7.9 6.6 5.6
Calcium (8.2–10 mg/dl) 9.9 9.9 9.7 10.1
Calcium × phosphorus (<65 mg2/dl2 for <12 yr) 71 78 64 56
1,25-(OH)2 Vitamin D3 (24–86 pg/ml) 84 59
Intact PTH (15–65 pg/ml) 21 11.2
TRP (85%–95%) 95 97.2 93
TP/GFR (age specific mean 4.4 mg/dl; ref. 24) 6.1 6.5 5.2
iFGF23 (< 52 pg/ml) 13,000 7800 6900
CFGF23 (3M-17Y ≤ 230) 33,000 33,000 22,400
CRP ( < 4.99 mg/l) 1.7  < 0.15
ESR (0–42 mm/h) 37 12
Glucose (nonfasting < 200 mg/dl) 82 119 81  
(fasting)
433
Hemoglobin A1c (4%–6%) 10.7
Insulin (2.6–24.9 mcU/ml) 4.1
C-peptide (1.1–5 ng/ml) 0.8
Bicarbonate (22–29 mmol/l) 28 20 23
ACZ, acetazolamide; SEV, sevelamer; PTH, parathyroid hormone; TP, tubular maximum reabsorption of 
phosphorus; GFR, glomerular filtration rate; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
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ELISAs are generated against relatively small, defined polypep-
tides derived from the 2 ends of the FGF23 protein and would not 
be influenced by the existing patient’s autoantibodies. Studies 
with other pathogenic autoantibodies, including pulmonary alveo-
lar proteinosis and membranous nephropathy, have also used sim-
ilar antibody-based methods to establish that the protein levels of 
the granulocyte-macrophage CSF (GM-CSF) (15) and anti-phos-
pholipase A2 receptor (PLA2R) (16), respectively, are unchanged 
or increased in these autoimmune diseases. Finally, our concor-
dant findings from 2 different commercial ELISA assays showing 
comparable results with elevated FGF23 protein levels potentially 
support the validity of this approach.
Based on the elevated FGF23 autoantibodies found in the 
patient, we tested the effect of FGF23 autoantibodies on FGF23 
signaling in an in vitro functional assay. Human embryonic kid-
ney cells (HEK293) stably transfected with the full-length trans-
membrane form of mouse Klotho (17) were treated with vehicle 
(PBS), recombinant human FGF23 R176Q, or basic FGF (bFGF) in 
the presence of either 2% plasma from our patient or 2% human 
control plasma. Recombinant FGF23 increased early growth 
response 1 (EGR1) mRNA expression in a dose-dependent man-
ner, whereas the patient’s plasma blocked the FGF23-dependent 
increase in EGR1 mRNA expression. The inhibitory effect of the 
patient’s plasma on EGR1 mRNA expression was overcome with 
the addition of 100 ng/ml FGF23 (Figure 3A). Control plasma had 
no effect on EGR1 mRNA expression at any FGF23 concentration 
(Figure 3B). Recombinant bFGF increased EGR1 mRNA expres-
sion independently of the patient’s plasma (Figure 3C), indicating 
that autoantibodies present in our patient’s plasma are specific in 
blocking the action of FGF23.
FGF23 binding to the FGFR1-Klotho receptor complex 
leads to ERK1/2 phosphorylation. We analyzed FGF23-depen-
in nature. Based on previously described LIPS tests for IA-2 (13) 
and GAD65 (14) autoantibodies, our patient demonstrated sero-
positive autoantibodies against IA-2 (Figure 2A) and seronega-
tive autoantibodies to GAD65 (Figure 2B), consistent with results 
obtained at diagnosis of T1DM. In order to test the hypothesis that 
autoantibodies might be directed against extracellular compo-
nents of the FGF23-signaling pathway, light-emitting luciferase 
fusion proteins for FGF23, FGFR1, and Klotho were generated for 
LIPS autoantibody profiling (12). Remarkably, the patient showed 
very high levels of autoantibodies against the FGF23-Gaussia 
luciferase fusion protein. These were 60-fold higher than those 
of other patients with HFTC due to mutations in GALNT3 (Figure 
2C). Moreover, patients with a variety of other autoimmune dis-
eases including Sjögren syndrome, systemic lupus erythematosus, 
vasculitis, and T1DM, were all seronegative for FGF23 autoanti-
bodies (Figure 2C). No significant detectable immunoreactivity 
was found against FGFR1 (Figure 2D) and Klotho (Figure 2E), as 
the autoantibody levels in the patient were comparable to those 
of other patients with HFTC and healthy controls. These findings 
demonstrate the patient had elevated levels of autoantibodies that 
were selectively against FGF23, but not against the corresponding 
receptor proteins for this ligand. Because FGF23 autoantibody 
titers were only measured at 2 time points, a potential correlation 
between autoantibody levels and blood phosphorus, FGF23, and 
1,25D could not be evaluated.
While we have not mapped the regions of FGF23 reacting 
with the patient’s autoantibodies, it is likely that the patient har-
bors a complex mixture of autoantibodies that target both linear 
and conformational epitopes of FGF23 and block the action of 
FGF23 on its receptor. Interestingly, the patient’s autoantibod-
ies did not interfere with the iFGF23 or CFGF23 ELISA assays. 
This is likely explained by the fact that the antibodies used in the 
Figure 1. Clinical presentation and radiographs of patient with tumoral 
calcinosis. (A) Tumoral calcinosis (arrows) of the lateral right hip at initial 
presentation to the NIH at 7 years, 3 months old. (B) Radiograph of the 
lesion revealed a soft tissue mass with amorphous calcifications around 
the right greater trochanter consistent with tumoral calcinosis. Repeat 
evaluation 9 months after initial presentation while on phosphate-lower-
ing medications (sevelamer and acetazolamide) and a low-phosphate diet 
showed decrease in the size of the tumoral calcinosis (arrows) on physical 
exam (C) and repeat radiograph (D).
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common variable immunodeficiency-associated autoimmune 
cytopenias (22), and cytotoxic T lymphocyte–associated protein 
4 (CTLA4) haploinsufficiency-associated immune dysregulation 
(23). Evaluation of T and B cell clonality was performed via PCR 
amplified for detection of immunoglobulin (IgH and IgK loci) and 
T cell receptor gene rearrangements. No significant T or B cell 
populations were identified. The subject was screened for auto-
antibodies associated with other autoimmune diseases and did 
not demonstrate autoantibodies to thyroglobulin, thyroid perox-
idase, tissue transglutaminase, intrinsic factor, parietal cells, and 
21-hydroxylase. He had normal immunoglobulin (IgG, IgA, and 
IgM) levels. Although the exact mechanism involved in the gener-
ation of anti-FGF23 autoantibodies in this subject is unknown, we 
speculate that autoreactive B cells not identified in the immune 
cell evaluation and/or epitope spreading in the context of T1DM 
might be responsible. Given the lack of an identifiable target for 
treatment, immunomodulatory medications were not recom-
mended for this patient.
Here, we describe what we believe is the first case of pathogen-
ic autoantibodies that target FGF23, causing hyperphosphatemic 
tumoral calcinosis. This observation is supported by identification 
of elevated levels of FGF23 autoantibodies, which, in vitro, block 
FGF23 action at the level of the FGFR1-Klotho receptor complex. 
We speculate that the FGF23 autoantibodies likely sequester 
FGF23 and prevent it from interacting with its receptor to promote 
normal signal transduction. The present data depict a pathophys-
dent phosphorylation of ERK1/2 in HEK293-Klotho cells in the 
presence or absence of patient or control plasma. Recombinant 
FGF23 significantly increased ERK1/2 phosphorylation, which 
was blocked by the patient’s plasma (Figure 3, D and G), suggest-
ing that the patient’s plasma blocks FGF23 binding to its receptor. 
Control plasma did not interfere with ERK1/2 phosphorylation 
(Figure 3, E and H). Furthermore, bFGF increased ERK1/2 phos-
phorylation, but the patient’s plasma had no inhibitory effect on 
ERK1/2 phosphorylation upon bFGF treatment (Figure 3, F and I). 
Changes in EGR1 protein levels were not assessed in the in vitro 
assay, given that the patient’s plasma with FGF23 was shown 
to block both EGR1 expression and ERK1/2 phosphorylation, 
which is not seen with control plasma/FGF23 or the patient’s 
plasma/bFGF. This is comparable to what has been shown in the 
Hyp mouse, which, when treated with an ERK1/2 inhibitor, had 
decreased FGF23 signaling and increased serum phosphorus, 
1,25D, and skeletal mineralization (18, 19).
Given the onset of 2 autoimmune diseases within 2 years, we 
examined the patient’s autoimmune and immunological charac-
teristics. Lymphocyte immunophenotyping using flow cytometry 
was performed. The patient had an overall normal cell profile 
with normal plasmablasts and total B cells with typical repre-
sentation of immature, transitional, and memory B cell subsets. 
He had low levels of the autoreactive CD21loCD38lo B cell subset 
(20), which is enriched in patients with autoimmune polyendo-
crinopathy-candidiasis-ectodermal dystrophy (APECED) (21), 
Figure 2. LIPS detection of autoantibodies. LIPS evaluation revealed the patient (red star) had seropositive autoantibodies against IA-2 (A), consistent 
with the diagnosis of T1DM, and seronegative autoantibodies to GAD65 (B). The patient showed very elevated levels of autoantibodies against FGF23 that 
were 60-fold higher than those of other patients with HFTC/HHS. The patient also had substantially higher levels of FGF23 autoantibodies compared with 
healthy controls and other patients with a variety of autoimmune diseases. SS, Sjögren’s syndrome; SLE, systemic lupus erythematosus; vasc, vasculitis. 
(C). The patient (red star) had levels of autoantibodies to FGFR1 (D) and Klotho (E) that were similar to those of other patients with HFTC and healthy 
controls. Dotted lines show mean light units (LU) value plus 3 SDs of the serum samples from healthy controls (14). Neg, negative.
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Figure 3. The effect of patient plasma on FGF23 signaling in HEK293-Klotho cells. Relative EGR1 mRNA expression compared with 18S rRNA in HEK293-
Klotho cells treated for 2 hours with either recombinant human FGF23 (vehicle, 25, 50, or 100 ng/ml) (A and B) or recombinant human bFGF (vehicle or 
10 ng/ml) (C) and ±2% patient plasma (A and C) or ±2% control plasma (B). n = 3. Single independent experiments were normalized to their untreated 
controls. Fold change of phosphorylated ERK1/2 (p-ERK1/2) protein abundance compared with ERK1/2 in HEK293-Klotho cells treated for 15 minutes with 
either vehicle, recombinant human FGF23 (25 ng/ml) (D, E, G, H), or recombinant human bFGF (10 ng/ml) (F and I) and ±2% patient plasma (D, F, G, I) or 
±2% control plasma (E and H). n = 3–6. Single independent experiments were normalized to vehicle control. Representative blots of single experiments 
show decreased p-ERK1/2 protein abundance with recombinant FGF23 (25 ng/ml) compared with vehicle-treated cells in the presence of patient’s plasma 
(G). Addition of control plasma in the presence of FGF23 resulted in no change in p-ERK1/2 protein abundance (H). There was no change in p-ERK1/2 pro-
tein abundance with bFGF (10 ng/ml) in the presence of patient’s plasma (I). Data are presented as mean + SD, and 2-way ANOVA followed by Tukey’s test 
for multiple comparisons was used for statistical analysis. *P < 0.05.
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